14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TPST vs FEMY: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Femasys Inc. (FEMY) is the stronger overall head-to-head candidate over Tempest Therapeutics, Inc. (TPST) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TPST carries a Unified Composite Score of 39.3/100 (SELL) at $0.34 (N/M Forward P/E, 0.0% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin).
Growth vs. Quality Trade-Off: FEMY earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. TPST 39.3/100 SELL) and 4.01β · 72% Vol risk profile, whereas TPST leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: TPST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.7); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ TPST vs FEMY Key Questions & Quantitative Answers
As of Nov 16, 2026, Femasys Inc. (FEMY) is the stronger overall head-to-head candidate over Tempest Therapeutics, Inc. (TPST) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TPST carries a Unified Composite Score of 39.3/100 (SELL) at $0.34 (N/M Forward P/E, 0.0% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin). Growth vs. Quality Trade-Off: FEMY earns the overall head-to-head edge with a stronger Unified Composite Score (52.6/100 HOLD vs. TPST 39.3/100 SELL) and 4.01β · 72% Vol risk profile, whereas TPST leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TPST is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.7); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
TPST leads the Growth & Scale pillar: TPST posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). Across the 8-period historical trajectory (FY2016 to FY2025), TPST cumulative revenue shifted N/A while FEMY shifted N/A. In operating R&D and SG&A reinvestment, TPST deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.
FEMY screens cheaper on headline valuation multiples. TPST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TPST (-1797.6% ROE) versus FEMY (-425.0% ROE) capital efficiency.
In options market volatility and institutional positioning, TPST carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.75β · 89% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.